bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
Authors: Griffin Rosalie , Hanson Heidi A. , Avery Brian J. , Madsen Michael J. , Sborov Douglas W. , Camp Nicola J.
Published: April 2023

Cox regression beta coefficients for overall survival (OS), progression free survival (PFS), and time to treatment failure (TTF). Beta coefficients are by per spectra standard deviation. The quantitative spectra risk score for an outcome is the weighted sum of the spectra retained in its model based on their beta coefficients.
Supplemental Figure S4 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
Authors: Griffin Rosalie , Hanson Heidi A. , Avery Brian J. , Madsen Michael J. , Sborov Douglas W. , Camp Nicola J.
Published: April 2023

Kaplan-Meier curves of overall survival by spectra and UAMS risk-groups in the CoMMpass data. CoMMpass patients were assigned to high and low risk separately using the OS Spectra score and the UAMS score (See Methods, Comparison to the UAMS risk score). Blue and orange lines: both methods agree on patient's risk category. Purple line: Spectra correctly identified high-risk patients (poorer survival) that are misclassified as low risk by UAMS. Green line: Spectra correctly identified low-risk patients (better survival) that are misclassified as high risk by UAMS.
Supplemental Figure S2 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
Authors: Griffin Rosalie , Hanson Heidi A. , Avery Brian J. , Madsen Michael J. , Sborov Douglas W. , Camp Nicola J.
Published: April 2023

Diagram of predictive modeling.
Supplemental Figure S1 from Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
Authors: Griffin Rosalie , Hanson Heidi A. , Avery Brian J. , Madsen Michael J. , Sborov Douglas W. , Camp Nicola J.
Published: April 2023

A color analogy to illustrate the advantages of spectra variables for modeling. a) Individual observations of color. b) Dimension Reduction (additive color theory), all colors can be represented using 3 quantitative RGB variables. c) Standard-use, hierarchical clustering identifies 3 groups. Each sample is categorized into a group (A, B or C). Subsequent modeling uses one categorical variable. d) Multivariable modeling with quantitative spectra variables, multiple spectra integrated directly into a multivariable analysis. Each uncorrelated variable can be assessed separately for its predictive value for an outcome. This implementation retains higher resolution because the variables are quantitative and retain integrity to the initial data. Note, lower-resolution versions of xB and xG can be achieved using hierarchical groups, but the loss of quantification may lose power. xR cannot be captured by any group ordering and associations for this spectrum would be lost using hierarchical groups. Three dimensions shown for visualization purposes; transcriptome data is likely to harbor a higher number of dimensions.
Table S3B from Linking Physical Activity to Breast Cancer Risk via Inflammation, Part 1: The Effect of Physical Activity on Inflammation
Authors: Swain Christopher T.V. , Drummond Ann E. , Milne Roger L. , English Dallas R. , Brown Kristy A. , Lou Makayla W.C. , Boing Leonessa , Bageley Amy , Skinner Tina L. , van Roekel Eline H. , Moore Melissa M. , Gaunt Tom R. , Martin Richard M. , Lewis Sarah J. , Lynch Brigid M.
Published: April 2023

Supplementary Table 3B presents the risk of bias for non-randomised interventions, using the ROBINS-I
Table S2B from Linking Physical Activity to Breast Cancer Risk via Inflammation, Part 1: The Effect of Physical Activity on Inflammation
Authors: Swain Christopher T.V. , Drummond Ann E. , Milne Roger L. , English Dallas R. , Brown Kristy A. , Lou Makayla W.C. , Boing Leonessa , Bageley Amy , Skinner Tina L. , van Roekel Eline H. , Moore Melissa M. , Gaunt Tom R. , Martin Richard M. , Lewis Sarah J. , Lynch Brigid M.
Published: April 2023

Supplementary Table 2B presents the study characteristics of randomised cross-over trials
Figure S4 from Linking Physical Activity to Breast Cancer Risk via Inflammation, Part 1: The Effect of Physical Activity on Inflammation
Authors: Swain Christopher T.V. , Drummond Ann E. , Milne Roger L. , English Dallas R. , Brown Kristy A. , Lou Makayla W.C. , Boing Leonessa , Bageley Amy , Skinner Tina L. , van Roekel Eline H. , Moore Melissa M. , Gaunt Tom R. , Martin Richard M. , Lewis Sarah J. , Lynch Brigid M.
Published: April 2023

Supplementary Figure 4 presents funnel plots for physical activity to inflammatory biomarkers meta-analyses
Figure S1A from Linking Physical Activity to Breast Cancer Risk via Inflammation, Part 1: The Effect of Physical Activity on Inflammation
Authors: Swain Christopher T.V. , Drummond Ann E. , Milne Roger L. , English Dallas R. , Brown Kristy A. , Lou Makayla W.C. , Boing Leonessa , Bageley Amy , Skinner Tina L. , van Roekel Eline H. , Moore Melissa M. , Gaunt Tom R. , Martin Richard M. , Lewis Sarah J. , Lynch Brigid M.
Published: April 2023

Supplementary Figure 1A presents forest plots for physical activity and CRP, by menopausal status
Table S7 from Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry
Authors: Haslam Danielle E. , John Esther M. , Knight Julia A. , Li Zhongyu , Buys Saundra S. , Andrulis Irene L. , Daly Mary B. , Genkinger Jeanine M. , Terry Mary Beth , Zhang Fang Fang
Published: April 2023

Table S7 Shows Hazard Ratios and 95% Confidence Intervals for Total Mortality in Women Diagnosed with Breast Cancer According to Diet Quality Index Stratified by Race and Ethnicity
Table S6 from Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry
Authors: Haslam Danielle E. , John Esther M. , Knight Julia A. , Li Zhongyu , Buys Saundra S. , Andrulis Irene L. , Daly Mary B. , Genkinger Jeanine M. , Terry Mary Beth , Zhang Fang Fang
Published: April 2023

Table S6 Shows Hazard Ratios and 95% Confidence Intervals for All-Cause Mortality in Women Diagnosed with Breast Cancer According to AHEI and aMED, Stratified by Patient and Treatment Characteristics
Table S4 from Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry
Authors: Haslam Danielle E. , John Esther M. , Knight Julia A. , Li Zhongyu , Buys Saundra S. , Andrulis Irene L. , Daly Mary B. , Genkinger Jeanine M. , Terry Mary Beth , Zhang Fang Fang
Published: April 2023

Table S4 Shows Hazard Ratios and 95% Confidence Intervals for Risk of Breast Cancer- and CVD-Specific Mortality in Women Diagnosed with Breast Cancer According to Dietary Quality Indices in the Northern California Breast Cancer Family Registry Site
Table S2 from Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry
Authors: Haslam Danielle E. , John Esther M. , Knight Julia A. , Li Zhongyu , Buys Saundra S. , Andrulis Irene L. , Daly Mary B. , Genkinger Jeanine M. , Terry Mary Beth , Zhang Fang Fang
Published: April 2023

Table S2 Shows Pearson's Correlation Coefficients (r) for Diet Quality Index Scores
Table S1 from Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry
Authors: Haslam Danielle E. , John Esther M. , Knight Julia A. , Li Zhongyu , Buys Saundra S. , Andrulis Irene L. , Daly Mary B. , Genkinger Jeanine M. , Terry Mary Beth , Zhang Fang Fang
Published: April 2023

Table S1 Shows Criteria for Maximum Scoring for 4 Diet Quality Indices Using Standardized Cup and Ounce Equivalents from the MyPyramid Equivalents Database
Supplementary Figure S4 from Neighborhood Socioeconomic Status and Racial and Ethnic Survival Disparities in Oral Cavity and Laryngeal Cancer
Authors: Liu Yupeng , Zhong Lydia , Puram Sidharth V. , Mazul Angela L.
Published: April 2023

Four KM curves depicting the 5-year overall survival of larynx cancer patients in Asian subgroups.
Supplementary Figure S1 from Neighborhood Socioeconomic Status and Racial and Ethnic Survival Disparities in Oral Cavity and Laryngeal Cancer
Authors: Liu Yupeng , Zhong Lydia , Puram Sidharth V. , Mazul Angela L.
Published: April 2023

KM curve depicting 5-year overall survival of oral cavity cancer patients.
Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Geethakumari Praveen Ramakrishnan , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: April 2023

Supplemental Tables and Protocol Description
Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Geethakumari Praveen Ramakrishnan , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: April 2023

Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A) Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.
Supplementary Figure S1 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

Study Schema. This is a single-arm, phase II trial combining durvalumab and cetuximab in patients with recurrent/metastatic HNSCC. Patients received the loading dose of cetuximab followed by the addition of durvalumab with weekly cetuximab doses. CT scans were done every eight weeks. Blood draws for correlatives occurred at screening, after the loading dose of cetuximab, and after the first dose of durvalumab and cetuximab combined.Abbreviations: CT, computed tomography; POD, progression of disease
Supplementary Table S5 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riuye , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2023

Adverse Events: Grade 3
Supplementary Methods S1 from Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Authors: Schoen Robert E. , Boardman Lisa A. , Cruz-Correa Marcia , Bansal Ajay , Kastenberg David , Hur Chin , Dzubinski Lynda , Kaufman Sharon F. , Rodriguez Luz M. , Richmond Ellen , Umar Asad , Szabo Eva , Salazar Andres , McKolanis John , Beatty Pamela , Pai Reetesh K. , Singhi Aatur D. , Jacqueline Camille M. , Bao Riuye , Diergaarde Brenda , McMurray Ryan P. , Strand Carrie , Foster Nathan R. , Zahrieh David M. , Limburg Paul J. , Finn Olivera J.
Published: April 2023

supplementary methods: trial administration
Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Omlin Aurelius , Cathomas Richard , von Amsberg Gunhild , Reuter Christoph , Feyerabend Susan , Loidl Wolfgang , Boegemann Martin , Lorch Anja , Heidenreich Axel , Tsaur Igor , Larcher-Senn Julian , Buck Stefan A.J. , Mathijssen Ron H.J. , Jaehde Ulrich , Gillessen Silke , Joerger Markus
Published: April 2023

Representativeness of Study Participants
Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Omlin Aurelius , Cathomas Richard , von Amsberg Gunhild , Reuter Christoph , Feyerabend Susan , Loidl Wolfgang , Boegemann Martin , Lorch Anja , Heidenreich Axel , Tsaur Igor , Larcher-Senn Julian , Buck Stefan A.J. , Mathijssen Ron H.J. , Jaehde Ulrich , Gillessen Silke , Joerger Markus
Published: April 2023

CONSORT Diagram
Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
Authors: Schober Sebastian Johannes , Schoening Caroline , Eck Jennifer , Middendorf Charlotte , Lutsch Julia , Knoch Pia , von Ofen Anna Josefine , Gassmann Hendrik , Thiede Melanie , Hauer Julia , Kolk Andreas , Mantwill Klaus , Gschwend Jürgen E. , Burdach Stefan E.G. , Nawroth Roman , Thiel Uwe , Holm Per Sonne
Published: April 2023

Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.
Figure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Authors: Cole Alexander J. , Panesso-Gómez Santiago , Shah Jaynish S. , Ebai Tonge , Jiang Qi , Gumusoglu-Acar Ece , Bello Maya G. , Vlad Anda , Modugno Francesmary , Edwards Robert P. , Buckanovich Ronald J.
Published: April 2023

Supplementary Figure 4. The effect of ATF2 siRNA on gene expression and PT340 FST induced chemoresistance. A. Schematic detailing the transwell experiments. CellTrace Violet cells were sorted for rapidly dividing (Dim) or quiescent cells (Bright) which were then plated in transwell chambers either as Dim:Dim or Bright:Dim. Cells were untreated or treated with taxol alone or in combination with IgG or anti-FST antibody. Cell counts were performed on the dim cells and data was expressed as fold chnage. B. Relative ATF2 gene expression of PT412 and PT340 treated with scrambled siRNA or two independent ATF2 siRNAs (ATF2 siRNA #1 and #2). C. Viable cell number of PT340 cells treated with control scrambled siRNA or knocked down with ATF2 siRNA and treated with cisplatin +/- FST. *P<0.05, ns = not significant.
Data from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
Authors: Gulati Shuchi , Crist McKenzie , Riaz Muhammed Kashif , Takiar Vinita , Lehn Maria , Monroe Ilaina , Palackdharry Sarah , Kurtzweil Nicky , Jandarov Roman , Harun Nusrat , Wise-Draper Trisha M.
Published: April 2023

AbstractPurpose:
The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and suppression of antitumor immunity. We hypothesized that adding an immune-checkpoint inhibitor (ICI) could overcome this and lead to an enhanced antitumor response.
Patients and Methods:
A phase II study of cetuximab and durvalumab in metastatic HNSCC was conducted. Eligible patients had measurable disease. Patients who had received both cetuximab and an ICI were excluded. The primary endpoint was objective response rate (ORR) by RECIST 1.1 at 6 months.
Results:
As of April 2022, 35 patients enrolled, of whom 33 received at least 1 dose of durvalumab and were included in the response analysis. Eleven patients (33%) had received prior platinum-based chemotherapy, 10 an ICI (30%), and 1 patient (3%) cetuximab. ORR was 39% (13/33) with a median duration of response of 8.6 months [95% confidence interval (CI): 6.5–16.8]. Median progression-free and overall survivals were 5.8 months (95% CI: 3.7–14.1) and 9.6 months (95% CI: 4.8–16.3), respectively. There were 16 grade 3 treatment-related adverse events (TRAE) and one grade 4 TRAE, with no treatment-related deaths. Overall and progression-free survival did not correlate with PD-L1 status. NK cell cytotoxic activity was increased by cetuximab and further increased with the addition of durvalumab in responders.
Conclusions:
The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.
Supplementary Figure 3 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
Authors: Elkins Kristi , Zheng Bing , Go MaryAnn , Slaga Dionysos , Du Changchun , Scales Suzie J. , Yu Shang-Fan , McBride Jacqueline , de Tute Ruth , Rawstron Andy , Jack Andrew S. , Ebens Allen , Polson Andrew G.
Published: April 2023

PDF file - 48KB, In vivo efficacy of anti-FcRL5-MC-vc-PAB-MMAE in combination with bortezomib
Supplementary Figure Legend from Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene
Authors: Lu Xiaohong , Wei Wenbin , Fenton Janine , Nahorski Michael S. , Rabai Erzsebet , Reiman Anne , Seabra Laurence , Nagy Zsuzsanna , Latif Farida , Maher Eamonn R.
Published: April 2023

Supplementary Figure Legend from Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene
Supplementary Methods, Table 1, Figure Legends 1-2 from Inhibition of Dynamin by Dynole 34-2 Induces Cell Death following Cytokinesis Failure in Cancer Cells
Authors: Chircop Megan , Perera Swetha , Mariana Anna , Lau Hui , Ma Maggie P.C. , Gilbert Jayne , Jones Nigel C. , Gordon Christopher P. , Young Kelly A. , Morokoff Andrew , Sakoff Jennette , O'Brien Terence J. , McCluskey Adam , Robinson Phillip J.
Published: April 2023

PDF file - 130K
Supplementary Table 3 from Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis
Authors: Huang Hui-Lin , Weng Heng-You , Wang Lu-Qin , Yu Chun-Hong , Huang Qiao-Juan , Zhao Pan-Pan , Wen Jun-Zhi , Zhou Hui , Qu Liang-Hu
Published: April 2023

PDF file - 75K, List of top 12 transcription factors that are most correlated with the potency of oridonin.
Supplementary Figure 6 from A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
Authors: Visnyei Koppany , Onodera Hideyuki , Damoiseaux Robert , Saigusa Kuniyasu , Petrosyan Syuzanna , De Vries David , Ferrari Denise , Saxe Jonathan , Panosyan Eduard H. , Masterman-Smith Michael , Mottahedeh Jack , Bradley Kenneth A. , Huang Jing , Sabatti Chiara , Nakano Ichiro , Kornblum Harley I.
Published: April 2023

PDF File - (523K) - OLDA, Emetine, 5256360 and 5560509 inhibit proliferation of sphere cultured GBM312 cells, using CFSE (carboxyfluorescein diacetate, succinimidyl ester) cell tracing experiments Proliferative inhibition is graphically represented by an increase in fluorescence or a shift to the right, away from that of the control. A proliferation index (PI) is a numerical value generated for each sample that measures the total increase in cell number divided by the original parent number. PI's are expressed as a percent of control: Emetine (0.2�M)- 18.6%, OLDA (4�M)- 16.0%, Compound 33 (2�M)- 31%, and Compound 62 (2�M)- 24.3%.
Supplementary Figure 3 from Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis
Authors: Huang Hui-Lin , Weng Heng-You , Wang Lu-Qin , Yu Chun-Hong , Huang Qiao-Juan , Zhao Pan-Pan , Wen Jun-Zhi , Zhou Hui , Qu Liang-Hu
Published: April 2023

PDF file - 33K, Oridonin increases Fbw7 expression after short-term treatment.
Supplementary Figures 1-3 from Linear Chain PEGylated Recombinant Bacillus Thiaminolyticus Thiaminase I Enzyme Has Growth Inhibitory Activity against Lymphoid Leukemia Cell Lines
Authors: Daily Abigail , Liu Shuqian , Bae Younsoo , Bhatnagar Saloni , Moscow Jeffrey A.
Published: April 2023

PDF file - 236K
Supplementary Table 1 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 249K
Supplementary Figure 7 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 34K
Supplementary Figure 6 from Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
Authors: Zwaagstra John C. , Sulea Traian , Baardsnes Jason , Lenferink Anne E.G. , Collins Cathy , Cantin Christiane , Paul-Roc Béatrice , Grothe Suzanne , Hossain Sazzad , Richer Louis-Philippe , L'Abbé Denis , Tom Roseanne , Cass Brian , Durocher Yves , O'Connor-McCourt Maureen D.
Published: April 2023

PDF file, 243KB, Improved neutralization of BMP-2 using single-chain bivalent trap (BMPR1a)2 compared to monovalent receptor BMPR1a-ED.
Supplementary Figure 4 from Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps
Authors: Zwaagstra John C. , Sulea Traian , Baardsnes Jason , Lenferink Anne E.G. , Collins Cathy , Cantin Christiane , Paul-Roc Béatrice , Grothe Suzanne , Hossain Sazzad , Richer Louis-Philippe , L'Abbé Denis , Tom Roseanne , Cass Brian , Durocher Yves , O'Connor-McCourt Maureen D.
Published: April 2023

PDF file, 971KB, Assessment of the effects of TGF-B and (TBRII)2 trap on 4T1 cells in vitro.
Supplementary Figure 3 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 1.5MB
Supplementary Figure 2 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 64K
Supplementary Figure 1 from Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Authors: Bialkowska Agnieszka B. , Crisp Melissa , Bannister Thomas , He Yuanjun , Chowdhury Sarwat , Schürer Stephan , Chase Peter , Spicer Timothy , Madoux Franck , Tian Chenlu , Hodder Peter , Zaharevitz Daniel , Yang Vincent W.
Published: April 2023

PDF file - 119K
Supplementary Methods from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Authors: Sunaga Noriaki , Shames David S. , Girard Luc , Peyton Michael , Larsen Jill E. , Imai Hisao , Soh Junichi , Sato Mitsuo , Yanagitani Noriko , Kaira Kyoichi , Xie Yang , Gazdar Adi F. , Mori Masatomo , Minna John D.
Published: April 2023

Supplementary Methods from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Supplementary Figure Legends 1-4 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Authors: Sunaga Noriaki , Shames David S. , Girard Luc , Peyton Michael , Larsen Jill E. , Imai Hisao , Soh Junichi , Sato Mitsuo , Yanagitani Noriko , Kaira Kyoichi , Xie Yang , Gazdar Adi F. , Mori Masatomo , Minna John D.
Published: April 2023

Supplementary Figure Legends 1-4 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Supplementary Table 2 from Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy
Authors: Bedi Atul , Chang Xiaofei , Noonan Kimberly , Pham Vui , Bedi Rishi , Fertig Elana J. , Considine Michael , Califano Joseph A. , Borrello Ivan , Chung Christine H. , Sidransky David , Ravi Rajani
Published: April 2023

PDF file - 70K, A, Serum levels of the indicated cytokines in patients with HNSCC and pleomorphic adenoma (non-cancer control). B, Comparison of serum TGF-beta1 levels in non-cancer controls and patients with HNSCC at the time of new diagnosis and at the time of recurrence. C, Comparison of serum levels of TGF-beta1 in patients with HPV-negative HNSCC at the time of diagnosis, and at two time points after the completion of treatment
Supplementary Table 2 from A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Authors: Hidalgo Manuel , Bruckheimer Elizabeth , Rajeshkumar N.V. , Garrido-Laguna Ignacio , De Oliveira Elizabeth , Rubio-Viqueira Belen , Strawn Steven , Wick Michael J. , Martell James , Sidransky David
Published: April 2023

Supplementary Table 2 from A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Supplementary Figures Legends 1-4 from Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage
Authors: Ha Kyungsoo , Fiskus Warren , Rao Rekha , Balusu Ramesh , Venkannagari Sreedhar , Nalabothula Narasimha Rao , Bhalla Kapil N.
Published: April 2023

Supplementary Figures Legends 1-4 from Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage
Supplementary Figure 1 from A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Authors: Hidalgo Manuel , Bruckheimer Elizabeth , Rajeshkumar N.V. , Garrido-Laguna Ignacio , De Oliveira Elizabeth , Rubio-Viqueira Belen , Strawn Steven , Wick Michael J. , Martell James , Sidransky David
Published: April 2023

Supplementary Figure 1 from A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Supplementary Figures 1-4 from Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage
Authors: Ha Kyungsoo , Fiskus Warren , Rao Rekha , Balusu Ramesh , Venkannagari Sreedhar , Nalabothula Narasimha Rao , Bhalla Kapil N.
Published: April 2023

Supplementary Figures 1-4 from Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage
Supplementary Figure Legend from PKCδ Regulates Death Receptor 5 Expression Induced by PS-341 through ATF4–ATF3/CHOP Axis in Human Lung Cancer Cells
Authors: Xu Linyan , Su Ling , Liu Xiangguo
Published: April 2023

PDF file, 53K.
Supplementary Data 6 from Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans
Authors: Moon Hyun-Seuk , Chamberland John P. , Aronis Konstantinos , Tseleni-Balafouta Sofia , Mantzoros Christos S.
Published: April 2023

PDF file - 119K, The cell culture and introduction of LKB1 siRNA were performed as described in detail in the "Methods" section. The cells were treated with adiponectin (20 �g/ml) for 24hr. C: Control; ssi: scrambled siRNA; si: LKB1 siRNA. All density values for each graph of interest are expressed as fold increases. All data were analyzed using one-way ANOVA followed by post-hoc test for multiple comparisons. Values are means (n=3) � SD. Means with different letters are significantly different, p<0.05.
Supplementary Figure 1 from PKCδ Regulates Death Receptor 5 Expression Induced by PS-341 through ATF4–ATF3/CHOP Axis in Human Lung Cancer Cells
Authors: Xu Linyan , Su Ling , Liu Xiangguo
Published: April 2023

PDF file, 216K, PS-341 induces ER stress response in NSCLC cells.
Supplementary Data 2 from Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans
Authors: Moon Hyun-Seuk , Chamberland John P. , Aronis Konstantinos , Tseleni-Balafouta Sofia , Mantzoros Christos S.
Published: April 2023

PDF file - 110K, Immunohistochemical analysis was performed as described in detail in the "Materials and Methods" section. A: AdipoR1 expression in tumor, B: AdipoR2 expression in tumor, C: tumor negative control, D: normal tissue control. Negative control tissues were subjected to immunochemistry, but not incubated with primary antibodies. (400x magnification for all) 7.Adiponectin receptor expression in benign endometrium vs. endometrial cancer samples ex vivo.
Supplementary Table 4 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

XLS file - 11K
Supplementary Table 1 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

XLS file - 18K
Supplementary Table 2 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 72K, List of genes with at least two fold change upon 72 h incubation with PD.
Supplementary Table 1 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 83K, List of genes with at least two fold change upon 24 h incubation with PD.
Supplementary Figure 5 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 398K, Effects of cdk4 and cdk6 knockdown on Smad transcriptional activity.
Supplementary Figure 1 from An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Authors: Winter Georg E. , Rix Uwe , Lissat Andrej , Stukalov Alexey , Müllner Markus K. , Bennett Keiryn L. , Colinge Jacques , Nijman Sebastian M. , Kubicek Stefan , Kovar Heinrich , Kontny Udo , Superti-Furga Giulio
Published: April 2023

PDF file - 53K
Supplementary Figure 3 from Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Authors: Liu Fang , Korc Murray
Published: April 2023

PDF file, 735K, Effects of PD-0332991 on invasion and EMT of AsPC-1 cells.
Supplementary Figure 2 from Overexpression of Mitotic Centromere–Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel
Authors: Ganguly Anutosh , Yang Hailing , Cabral Fernando
Published: April 2023

Supplementary Figure 2 from Overexpression of Mitotic Centromere–Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel
Supplementary Methods from Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells
Authors: Merle Patrick , Evrard Bertrand , Petitjean Anne , Lehn Jean-Marie , Teulade-Fichou Marie-Paule , Chautard Emmanuel , De Cian Anne , Guittat Lionel , Tran Phong Lan Thao , Mergny Jean-Louis , Verrelle Pierre , Tchirkov Andreï
Published: April 2023

PDF file - 68K
Supplementary Figures 1-9 from Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells
Authors: Merle Patrick , Evrard Bertrand , Petitjean Anne , Lehn Jean-Marie , Teulade-Fichou Marie-Paule , Chautard Emmanuel , De Cian Anne , Guittat Lionel , Tran Phong Lan Thao , Mergny Jean-Louis , Verrelle Pierre , Tchirkov Andreï
Published: April 2023

PDF file - 246K
Supplementary Table 2 from High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
Authors: Muinelo-Romay Laura , Colas Eva , Barbazan Jorge , Alonso-Alconada Lorena , Alonso-Nocelo Marta , Bouso Marta , Curiel Teresa , Cueva Juan , Anido Urbano , Forteza Jeronimo , Gil-Moreno Antonio , Reventos Jaume , Lopez-Lopez Rafael , Abal Miguel
Published: April 2023

Supplementary Table 2 from High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
Supplementary Figure 2 from Integrin α6high Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma
Authors: Wang Lu , Wang Lingxian , Gu Yanhong , Shu Yongqian , Shen Yan , Xu Qiang
Published: April 2023

PDF file - 64K, Integrin a6 and CD13 co-express in multiple malignant cancer cell lines.
Supplementary Figure 3 from Targeting the Microtubular Network as a New Antimyeloma Strategy
Authors: Feng Rentian , Li Shirong , Lu Caisheng , Andreas Carrie , Stolz Donna B. , Mapara Markus Y. , Lentzsch Suzanne
Published: April 2023

PDF file - 43K, Effects of nocodazole alone or in combination with dexamethasone on myeloma tumor growth.
Supplementary Figure 1 from Targeting the Microtubular Network as a New Antimyeloma Strategy
Authors: Feng Rentian , Li Shirong , Lu Caisheng , Andreas Carrie , Stolz Donna B. , Mapara Markus Y. , Lentzsch Suzanne
Published: April 2023

PDF file - 52K, Confirmation of drug resistant phenotype of RPMI-multiple myeloma cell lines.
Supplementary Video and Figure Legends from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Authors: On Kin Fan , Chen Yue , Tang Ma Hoi , Chow Jeremy P.H. , Poon Randy Y.C.
Published: April 2023

Supplementary Video and Figure Legends from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Supplementary Figure 4 from A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXCR4-Expressing Melanoma Cells Due to Enhanced Serum Stability
Authors: Takekoshi Tomonori , Ziarek Joshua J. , Volkman Brian F. , Hwang Sam T.
Published: April 2023

PDF file, 77K, Full length blots of Figure 3B and Figure 5A.
Supplementary Figure 2 from A Locked, Dimeric CXCL12 Variant Effectively Inhibits Pulmonary Metastasis of CXCR4-Expressing Melanoma Cells Due to Enhanced Serum Stability
Authors: Takekoshi Tomonori , Ziarek Joshua J. , Volkman Brian F. , Hwang Sam T.
Published: April 2023

PDF file, 36K, Representative raw Calcium flux data of Figure 1F and that of CXCR4-negative B16 cells with proteins.
Supplementary Figures 1-5 from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
Authors: Faisal Amir , Vaughan Lynsey , Bavetsias Vassilios , Sun Chongbo , Atrash Butrus , Avery Sian , Jamin Yann , Robinson Simon P. , Workman Paul , Blagg Julian , Raynaud Florence I. , Eccles Suzanne A. , Chesler Louis , Linardopoulos Spiros
Published: April 2023

PDF file - 339K
Supplementary Figure Legends 1-5 from The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
Authors: Faisal Amir , Vaughan Lynsey , Bavetsias Vassilios , Sun Chongbo , Atrash Butrus , Avery Sian , Jamin Yann , Robinson Simon P. , Workman Paul , Blagg Julian , Raynaud Florence I. , Eccles Suzanne A. , Chesler Louis , Linardopoulos Spiros
Published: April 2023

PDF file - 101K
Supplementary Video 1 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Authors: On Kin Fan , Chen Yue , Tang Ma Hoi , Chow Jeremy P.H. , Poon Randy Y.C.
Published: April 2023

Supplementary Video 1 from Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01
Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models
Authors: Valiyeva Fatma , Jiang Fei , Elmaadawi Ahmed , Moussa Madeleine , Yee Siu-Pok , Raptis Leda , Izawa Jonathan I. , Yang Burton B. , Greenberg Norman M. , Wang Fen , Xuan Jim W.
Published: April 2023

Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models
Supplementary Tables 1-2 from Synthetic Triterpenoid Cyano Enone of Methyl Boswellate Activates Intrinsic, Extrinsic, and Endoplasmic Reticulum Stress Cell Death Pathways in Tumor Cell Lines
Authors: Ravanan Palaniyandi , Sano Renata , Talwar Priti , Ogasawara Satoshi , Matsuzawa Shu-ichi , Cuddy Michael , Singh Sanjay K. , Rao G.S.R. Subba , Kondaiah Paturu , Reed John C.
Published: April 2023

PDF file - 27K
Supplementary Figure 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
Authors: Bagley Rebecca G. , Kurtzberg Leslie , Weber William , Nguyen Tri-Hung , Roth Stephanie , Krumbholz Roy , Yao Min , Richards Brenda , Zhang Mindy , Pechan Peter , Schmid Steve , Scaria Abraham , Kaplan Johanne , Teicher Beverly A.
Published: April 2023

Supplementary Figure 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
Supplementary Figures 1-5 from Synthetic Triterpenoid Cyano Enone of Methyl Boswellate Activates Intrinsic, Extrinsic, and Endoplasmic Reticulum Stress Cell Death Pathways in Tumor Cell Lines
Authors: Ravanan Palaniyandi , Sano Renata , Talwar Priti , Ogasawara Satoshi , Matsuzawa Shu-ichi , Cuddy Michael , Singh Sanjay K. , Rao G.S.R. Subba , Kondaiah Paturu , Reed John C.
Published: April 2023

PDF file - 233K
Supplementary Figure Legends 1-5 from Synthetic Triterpenoid Cyano Enone of Methyl Boswellate Activates Intrinsic, Extrinsic, and Endoplasmic Reticulum Stress Cell Death Pathways in Tumor Cell Lines
Authors: Ravanan Palaniyandi , Sano Renata , Talwar Priti , Ogasawara Satoshi , Matsuzawa Shu-ichi , Cuddy Michael , Singh Sanjay K. , Rao G.S.R. Subba , Kondaiah Paturu , Reed John C.
Published: April 2023

PDF file - 90K
Supplementary Figure 3 from Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents
Authors: Rao Thapi D. , Rosales Nestor , Spriggs David R.
Published: April 2023

PDF file - 340K
Supplementary Figure 2 from Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents
Authors: Rao Thapi D. , Rosales Nestor , Spriggs David R.
Published: April 2023

PDF file - 253K
Supplementary Figure Legends from Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
Authors: Zhao Huajun , Lo Yuan-Hung , Ma Li , Waltz Susan E. , Gray Jerilyn K. , Hung Mien-Chie , Wang Shao-Chun
Published: April 2023

Supplementary Figure Legends from Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
Supplementary Figures 1-15 from Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
Authors: Lu Jianfeng , McEachern Donna , Sun Haiying , Bai Longchuan , Peng Yuefeng , Qiu Su , Miller Rebecca , Liao Jinhui , Yi Han , Liu Meilan , Bellail Anita , Hao Chunhai , Sun Shi-Yong , Ting Adrian T. , Wang Shaomeng
Published: April 2023

Supplementary Figures 1-15 from Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
Supplement 2 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Authors: Schramm Sarah-Jane , Mann Graham J.
Published: April 2023

Supplement 2 from Melanoma Prognosis: A REMARK-Based Systematic Review and Bioinformatic Analysis of Immunohistochemical and Gene Microarray Studies
Supplementary Table 1 from Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells
Authors: Gupta Seema , Koru-Sengul Tulay , Arnold Susanne M. , Devi Gayathri R. , Mohiuddin Mohammed , Ahmed Mansoor M.
Published: April 2023

PDF file - 69K
Supplementary Figure 1 from A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
Authors: Faibish Michael , Francescone Ralph , Bentley Brooke , Yan Wei , Shao Rong
Published: April 2023

Supplementary Figure 1 from A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
Supplementary Tables 1-3 from Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
Authors: Minematsu Tsuyoshi , Giacomini Kathleen M.
Published: April 2023

Supplementary Tables 1-3 from Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
Supplementary Figure 1 from Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
Authors: Minematsu Tsuyoshi , Giacomini Kathleen M.
Published: April 2023

Supplementary Figure 1 from Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
NMR Spectra from A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos
Authors: Vollmer Laura L. , Jiménez Maria , Camarco Daniel P. , Zhu Wei , Daghestani Hikmat N. , Balachandran Raghavan , Reese Celeste E. , Lazo John S. , Hukriede Neil A. , Curran Dennis P. , Day Billy W. , Vogt Andreas
Published: April 2023

NMR Spectra from A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos
Supplementary Figure 5 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
Authors: Nebbioso Angela , Pereira Raquel , Khanwalkar Harshal , Matarese Filomena , García-Rodríguez José , Miceli Marco , Logie Colin , Kedinger Valerie , Ferrara Felicetto , Stunnenberg Hendrik G. , de Lera Angel R. , Gronemeyer Hinrich , Altucci Lucia
Published: April 2023

PDF file - 53K
Supplementary Figure 4 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
Authors: Nebbioso Angela , Pereira Raquel , Khanwalkar Harshal , Matarese Filomena , García-Rodríguez José , Miceli Marco , Logie Colin , Kedinger Valerie , Ferrara Felicetto , Stunnenberg Hendrik G. , de Lera Angel R. , Gronemeyer Hinrich , Altucci Lucia
Published: April 2023

PDF file - 81K
Supplementary Figure 1 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
Authors: Nebbioso Angela , Pereira Raquel , Khanwalkar Harshal , Matarese Filomena , García-Rodríguez José , Miceli Marco , Logie Colin , Kedinger Valerie , Ferrara Felicetto , Stunnenberg Hendrik G. , de Lera Angel R. , Gronemeyer Hinrich , Altucci Lucia
Published: April 2023

PDF file - 64K
Supplementary Figures 1-11 from A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Authors: Torres Sofía , Lorente Mar , Rodríguez-Fornés Fátima , Hernández-Tiedra Sonia , Salazar María , García-Taboada Elena , Barcia Juan , Guzmán Manuel , Velasco Guillermo
Published: April 2023

Supplementary Figures 1-11 from A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Supplementary Table 1 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 63K, Oxaliplatin sensitivity data to the NCI-60 cell lines.
Supplementary Figure 2 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 110K, 14 formalin-fixed paraffin-embedded PDCCEs were arrayed, RMA normalized and base on a 3D principal components analysis, CRC057 was omitted from further analysis.
Supplementary Figures Legends 1-5, Table 1 from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Authors: Raina Deepak , Kosugi Michio , Ahmad Rehan , Panchamoorthy Govind , Rajabi Hasan , Alam Maroof , Shimamura Takeshi , Shapiro Geoffrey I. , Supko Jeffrey , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figures Legends 1-5, Table 1 from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Supplementary Figure 1 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 39K, Fifty-nine samples from the NCI-60 cell panel were RMA normalized and base on 3D principal components analysis, MCF-7 was ommitted from further analysis.
Supplementary Methods, Figure Legends 1-4 from Phenotypic Reversion of Invasive Neurofibromin-Deficient Schwannoma by FTS: Ras Inhibition Reduces BMP4/Erk/Smad Signaling
Authors: Barkan Batya , Kloog Yoel , Ehrlich Marcelo
Published: April 2023

Supplementary Methods, Figure Legends 1-4 from Phenotypic Reversion of Invasive Neurofibromin-Deficient Schwannoma by FTS: Ras Inhibition Reduces BMP4/Erk/Smad Signaling
Supplementary Figure 4 from Phenotypic Reversion of Invasive Neurofibromin-Deficient Schwannoma by FTS: Ras Inhibition Reduces BMP4/Erk/Smad Signaling
Authors: Barkan Batya , Kloog Yoel , Ehrlich Marcelo
Published: April 2023

Supplementary Figure 4 from Phenotypic Reversion of Invasive Neurofibromin-Deficient Schwannoma by FTS: Ras Inhibition Reduces BMP4/Erk/Smad Signaling
Supplementary Figure S2ABCDE from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Authors: Raina Deepak , Kosugi Michio , Ahmad Rehan , Panchamoorthy Govind , Rajabi Hasan , Alam Maroof , Shimamura Takeshi , Shapiro Geoffrey I. , Supko Jeffrey , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figure S2ABCDE from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells